HbA1c reductions up to 1.6 percentage points Weight trajectory: Weight loss had not plateaued by 52 weeks, indicating potential for further reduction with continued treatment Cardiometabolic: Improvements in waist circumference, blood pressure, hs-CRP, and lipid parameters Evidence level: Moderate -- well-designed phase 2 with NEJM publication, but single trial, no head-to-head comparisons
pre-bed required, AM optional Ipamorelin Loading 100 mcg (weeks 1-2) Frequency 1-2x daily Maintenance 100-200 mcg, 1-2x daily Route SubQ
Robert Kushner: Well, we're targeting a sweet spot in our biology, Mike, that we didn't really know was there, at least I didn't know what was there
Working with a mental health professional can provide strategies to cope with these feelings and improve mental health